Refining medulloblastoma subgroups
Menée au Royaume-Uni partir de 428 échantillons de médulloblastome primitif prélevés sur des patients pédiatriques (âgés de moins de 16 ans lors du diagnostic) puis validée sur 276 échantillons tumoraux archivés, cette étude de cohorte rétrospective définit 7 nouveaux sous-groupes moléculaires de la pathologie permettant d'améliorer la stratification des patients
Medulloblastoma is currently deemed to be composed of four molecular subgroups: WNT (MBWNT), SHH (MBSHH), group 3 (MBGrp3), and group 4 (MBGrp4).1 Reports from retrospective data collection have shown distinct clinical and biological characteristics and outcomes for the four subgroups, with the MBWNT subgroup having an excellent prognosis and patients in the MBGrp3 subgroup having very poor prognosis across several studies.2–5 However, substantial heterogeneity in clinical and molecular features still exists in these subgroups
The Lancet Oncology , commentaire, 2016